▶ 調査レポート

注意欠陥多動性障害(ADHD)薬の世界市場 2020年:メーカー別、地域別、種類・用途別

• 英文タイトル:Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが調査・発行した産業分析レポートです。注意欠陥多動性障害(ADHD)薬の世界市場 2020年:メーカー別、地域別、種類・用途別 / Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 / D005-02074資料のイメージです。• レポートコード:D005-02074
• 出版社/出版日:GlobalInfoResearch / 2020年5月
• レポート形態:英文、PDF、104ページ
• 納品方法:Eメール(納期2~3日)
• 産業分類:医療・製薬
• 販売価格(消費税別)
  Single User¥361,920 (USD3,480)▷ お問い合わせ
  Multi User¥542,880 (USD5,220)▷ お問い合わせ
  Corporate User¥723,840 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、注意欠陥多動性障害(ADHD)薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。注意欠陥多動性障害(ADHD)薬の種類別市場規模(覚せい剤、非覚せい剤)、用途別市場規模(小児科、青年期、成人)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・メーカー情報(販売量、市場シェア、製品概要、SWOT分析):Eli Lilly、Celltech Group、Janssen Pharmaceuticals, Inc.、Perdue Pharma、Novartis、Johnson & Johnson、Glaxosmith Kline、Takeda
・地域別グローバル市場分析 2015年-2020年
・注意欠陥多動性障害(ADHD)薬の北米市場(アメリカ、カナダ、メキシコ)
・注意欠陥多動性障害(ADHD)薬のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・注意欠陥多動性障害(ADHD)薬のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・注意欠陥多動性障害(ADHD)薬の南米市場(ブラジル、アルゼンチン)
・注意欠陥多動性障害(ADHD)薬の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:覚せい剤、非覚せい剤
・用途別分析:小児科、青年期、成人
・地域別市場規模予測 2021年-2025年
・販売チャネル、流通業者、代理店
・調査の結果・結論

Market Overview
The global Attention Deficit Hyperactivity Disorder (ADHD) Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Attention Deficit Hyperactivity Disorder (ADHD) Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Attention Deficit Hyperactivity Disorder (ADHD) Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Attention Deficit Hyperactivity Disorder (ADHD) Drug market has been segmented into
Stimulants
Non-Stimulants

By Application, Attention Deficit Hyperactivity Disorder (ADHD) Drug has been segmented into:
Pediatric
Adolescent
Adults

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Attention Deficit Hyperactivity Disorder (ADHD) Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Attention Deficit Hyperactivity Disorder (ADHD) Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Attention Deficit Hyperactivity Disorder (ADHD) Drug market.

The report offers in-depth assessment of the growth and other aspects of the Attention Deficit Hyperactivity Disorder (ADHD) Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Competitive Landscape and Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Share Analysis
Attention Deficit Hyperactivity Disorder (ADHD) Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Attention Deficit Hyperactivity Disorder (ADHD) Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Attention Deficit Hyperactivity Disorder (ADHD) Drug sales, revenue and market share for each player covered in this report.

The major players covered in Attention Deficit Hyperactivity Disorder (ADHD) Drug are:
Eli Lilly
Celltech Group
Janssen Pharmaceuticals, Inc.
Perdue Pharma
Novartis
Johnson & Johnson
Glaxosmith Kline
Takeda

Among other players domestic and global, Attention Deficit Hyperactivity Disorder (ADHD) Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Attention Deficit Hyperactivity Disorder (ADHD) Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Attention Deficit Hyperactivity Disorder (ADHD) Drug, with price, sales, revenue and global market share of Attention Deficit Hyperactivity Disorder (ADHD) Drug in 2018 and 2019.
Chapter 3, the Attention Deficit Hyperactivity Disorder (ADHD) Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Attention Deficit Hyperactivity Disorder (ADHD) Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Attention Deficit Hyperactivity Disorder (ADHD) Drug market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Attention Deficit Hyperactivity Disorder (ADHD) Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

Table of Contents

1 Market Overview
1.1 Attention Deficit Hyperactivity Disorder (ADHD) Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Stimulants
1.2.3 Non-Stimulants
1.3 Market Analysis by Application
1.3.1 Overview: Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Pediatric
1.3.3 Adolescent
1.3.4 Adults
1.4 Overview of Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Market
1.4.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Eli Lilly
2.1.1 Eli Lilly Details
2.1.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Eli Lilly SWOT Analysis
2.1.4 Eli Lilly Product and Services
2.1.5 Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Celltech Group
2.2.1 Celltech Group Details
2.2.2 Celltech Group Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Celltech Group SWOT Analysis
2.2.4 Celltech Group Product and Services
2.2.5 Celltech Group Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Janssen Pharmaceuticals, Inc.
2.3.1 Janssen Pharmaceuticals, Inc. Details
2.3.2 Janssen Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Janssen Pharmaceuticals, Inc. SWOT Analysis
2.3.4 Janssen Pharmaceuticals, Inc. Product and Services
2.3.5 Janssen Pharmaceuticals, Inc. Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Perdue Pharma
2.4.1 Perdue Pharma Details
2.4.2 Perdue Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Perdue Pharma SWOT Analysis
2.4.4 Perdue Pharma Product and Services
2.4.5 Perdue Pharma Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Novartis SWOT Analysis
2.5.4 Novartis Product and Services
2.5.5 Novartis Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Johnson & Johnson SWOT Analysis
2.6.4 Johnson & Johnson Product and Services
2.6.5 Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Glaxosmith Kline
2.7.1 Glaxosmith Kline Details
2.7.2 Glaxosmith Kline Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Glaxosmith Kline SWOT Analysis
2.7.4 Glaxosmith Kline Product and Services
2.7.5 Glaxosmith Kline Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Takeda
2.8.1 Takeda Details
2.8.2 Takeda Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Takeda SWOT Analysis
2.8.4 Takeda Product and Services
2.8.5 Takeda Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Attention Deficit Hyperactivity Disorder (ADHD) Drug Manufacturer Market Share in 2019
3.3.2 Top 6 Attention Deficit Hyperactivity Disorder (ADHD) Drug Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Market Share by Regions (2015-2020)
4.1.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Market Share by Regions (2015-2020)
4.2 North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
4.3 Europe Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
4.5 South America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Revenue and Market Share by Country
5.1.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Market Share by Country (2015-2020)
5.1.2 North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Market Share by Country (2015-2020)
5.2 United States Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
5.3 Canada Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
5.4 Mexico Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Revenue and Market Share by Country
6.1.1 Europe Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Market Share by Country (2015-2020)
6.1.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Market Share by Country (2015-2020)
6.2 Germany Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
6.3 UK Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
6.4 France Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
6.5 Russia Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
6.6 Italy Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Market Share by Regions (2015-2020)
7.2 China Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
7.3 Japan Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
7.4 Korea Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
7.5 India Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
7.7 Australia Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Revenue and Market Share by Country
8.1.1 South America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Market Share by Country (2015-2020)
8.1.2 South America Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Market Share by Country (2015-2020)
8.2 Brazil Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
8.3 Argentina Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
9.3 Turkey Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
9.4 Egypt Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
9.5 South Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Market Share by Type (2015-2020)
10.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Market Share by Type (2015-2020)
10.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Price by Type (2015-2020)
11 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Segment by Application
11.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Market Share by Application (2015-2020)
11.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Application (2015-2020)
11.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Price by Application (2015-2020)
12 Market Forecast
12.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Revenue and Growth Rate (2021-2025)
12.2 Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Forecast by Regions (2021-2025)
12.2.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Forecast (2021-2025)
12.2.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Forecast (2021-2025)
12.2.3 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Forecast (2021-2025)
12.2.4 South America Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Forecast (2021-2025)
12.2.5 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Forecast (2021-2025)
12.3 Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Forecast by Type (2021-2025)
12.3.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Forecast by Type (2021-2025)
12.3.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Share Forecast by Type (2021-2025)
12.4 Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Forecast by Application (2021-2025)
12.4.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Forecast by Application (2021-2025)
12.4.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US

List of Tables

Table 1. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Attention Deficit Hyperactivity Disorder (ADHD) Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 8. Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Drug Major Business
Table 9. Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Drug Total Revenue (USD Million) (2018-2019)
Table 10. Eli Lilly SWOT Analysis
Table 11. Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Drug Product and Services
Table 12. Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Celltech Group Basic Information, Manufacturing Base and Competitors
Table 14. Celltech Group Attention Deficit Hyperactivity Disorder (ADHD) Drug Major Business
Table 15. Celltech Group Attention Deficit Hyperactivity Disorder (ADHD) Drug Total Revenue (USD Million) (2018-2019)
Table 16. Celltech Group SWOT Analysis
Table 17. Celltech Group Attention Deficit Hyperactivity Disorder (ADHD) Drug Product and Services
Table 18. Celltech Group Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Janssen Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 20. Janssen Pharmaceuticals, Inc. Attention Deficit Hyperactivity Disorder (ADHD) Drug Major Business
Table 21. Janssen Pharmaceuticals, Inc. Attention Deficit Hyperactivity Disorder (ADHD) Drug Total Revenue (USD Million) (2018-2019)
Table 22. Janssen Pharmaceuticals, Inc. SWOT Analysis
Table 23. Janssen Pharmaceuticals, Inc. Attention Deficit Hyperactivity Disorder (ADHD) Drug Product and Services
Table 24. Janssen Pharmaceuticals, Inc. Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Perdue Pharma Basic Information, Manufacturing Base and Competitors
Table 26. Perdue Pharma Attention Deficit Hyperactivity Disorder (ADHD) Drug Major Business
Table 27. Perdue Pharma Attention Deficit Hyperactivity Disorder (ADHD) Drug Total Revenue (USD Million) (2018-2019)
Table 28. Perdue Pharma SWOT Analysis
Table 29. Perdue Pharma Attention Deficit Hyperactivity Disorder (ADHD) Drug Product and Services
Table 30. Perdue Pharma Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Novartis Basic Information, Manufacturing Base and Competitors
Table 32. Novartis Attention Deficit Hyperactivity Disorder (ADHD) Drug Major Business
Table 33. Novartis Attention Deficit Hyperactivity Disorder (ADHD) Drug Total Revenue (USD Million) (2018-2019)
Table 34. Novartis SWOT Analysis
Table 35. Novartis Attention Deficit Hyperactivity Disorder (ADHD) Drug Product and Services
Table 36. Novartis Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 38. Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Drug Major Business
Table 39. Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Drug Total Revenue (USD Million) (2018-2019)
Table 40. Johnson & Johnson SWOT Analysis
Table 41. Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Drug Product and Services
Table 42. Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Glaxosmith Kline Basic Information, Manufacturing Base and Competitors
Table 44. Glaxosmith Kline Attention Deficit Hyperactivity Disorder (ADHD) Drug Major Business
Table 45. Glaxosmith Kline Attention Deficit Hyperactivity Disorder (ADHD) Drug Total Revenue (USD Million) (2018-2019)
Table 46. Glaxosmith Kline SWOT Analysis
Table 47. Glaxosmith Kline Attention Deficit Hyperactivity Disorder (ADHD) Drug Product and Services
Table 48. Glaxosmith Kline Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Takeda Basic Information, Manufacturing Base and Competitors
Table 50. Takeda Attention Deficit Hyperactivity Disorder (ADHD) Drug Major Business
Table 51. Takeda Attention Deficit Hyperactivity Disorder (ADHD) Drug Total Revenue (USD Million) (2018-2019)
Table 52. Takeda SWOT Analysis
Table 53. Takeda Attention Deficit Hyperactivity Disorder (ADHD) Drug Product and Services
Table 54. Takeda Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales by Manufacturer (2018-2019) (K Pcs)
Table 56. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue by Manufacturer (2018-2019) (USD Million)
Table 57. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales by Regions (2015-2020) (K Pcs)
Table 58. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Market Share by Regions (2015-2020)
Table 59. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue by Regions (2015-2020) (USD Million)
Table 60. North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales by Countries (2015-2020) (K Pcs)
Table 61. North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Market Share by Countries (2015-2020)
Table 62. North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue by Countries (2015-2020) (USD Million)
Table 63. North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Countries (2015-2020)
Table 64. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales by Countries (2015-2020) (K Pcs)
Table 65. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Market Share by Countries (2015-2020)
Table 66. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue by Countries (2015-2020) (USD Million)
Table 67. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales by Regions (2015-2020) (K Pcs)
Table 68. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Market Share by Regions (2015-2020)
Table 69. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue by Regions (2015-2020) (USD Million)
Table 70. South America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales by Countries (2015-2020) (K Pcs)
Table 71. South America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Market Share by Countries (2015-2020)
Table 72. South America Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue by Countries (2015-2020) (USD Million)
Table 73. South America Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Countries (2015-2020)
Table 74. Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales by Countries (2015-2020) (K Pcs)
Table 75. Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Market Share by Countries (2015-2020)
Table 76. Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue by Countries (2015-2020) (USD Million)
Table 77. Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Countries (2015-2020)
Table 78. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales by Type (2015-2020) (K Pcs)
Table 79. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Share by Type (2015-2020)
Table 80. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue by Type (2015-2020) (USD Million)
Table 81. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Share by Type (2015-2020)
Table 82. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales by Application (2015-2020) (K Pcs)
Table 83. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Share by Application (2015-2020)
Table 84. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Forecast by Regions (2021-2025) (K Pcs)
Table 85. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Share Forecast by Regions (2021-2025)
Table 86. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Forecast by Type (2021-2025) (K Pcs)
Table 87. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Share Forecast by Type (2021-2025)
Table 88. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Forecast by Application (2021-2025)
Table 89. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Share Forecast by Application (2021-2025)
Table 90. Direct Channel Pros & Cons
Table 91. Indirect Channel Pros & Cons
Table 92. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Attention Deficit Hyperactivity Disorder (ADHD) Drug Picture
Figure 2. Global Sales Market Share of Attention Deficit Hyperactivity Disorder (ADHD) Drug by Type in 2019
Figure 3. Stimulants Picture
Figure 4. Non-Stimulants Picture
Figure 5. Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Market Share by Application in 2018
Figure 6. Pediatric Picture
Figure 7. Adolescent Picture
Figure 8. Adults Picture
Figure 9. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Status and Outlook (2015-2025) (USD Million)
Figure 10. United States Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 11. Canada Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Mexico Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Germany Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 14. France Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 15. UK Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Russia Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Italy Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 18. China Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Japan Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Korea Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 21. India Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Australia Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 24. Brazil Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Egypt Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Saudi Arabia Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 27. South Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Turkey Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Market Share by Manufacturer in 2019
Figure 30. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Manufacturer in 2019
Figure 31. Top 3 Attention Deficit Hyperactivity Disorder (ADHD) Drug Manufacturer (Revenue) Market Share in 2019
Figure 32. Top 6 Attention Deficit Hyperactivity Disorder (ADHD) Drug Manufacturer (Revenue) Market Share in 2019
Figure 33. Key Manufacturer Market Share Trend
Figure 34. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 35. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 36. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Regions (2015-2020)
Figure 37. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Regions in 2018
Figure 38. North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
Figure 39. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
Figure 41. South America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
Figure 42. Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020)
Figure 43. North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 44. North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Market Share by Countries (2015-2020)
Figure 45. North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Market Share by Countries in 2018
Figure 46. North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 47. North America Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Countries in 2018
Figure 48. United States Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 49. Canada Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 50. Mexico Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 51. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 52. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Countries (2015-2020)
Figure 53. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Countries in 2019
Figure 54. Germany Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 55. UK Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 56. France Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 57. Russia Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 58. Italy Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 60. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Market Share by Regions 2019
Figure 61. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Regions 2019
Figure 62. China Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 63. Japan Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 64. Korea Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 65. India Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 66. Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. South America Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 68. South America Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Market Share by Countries in 2019
Figure 69. South America Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Countries in 2019
Figure 70. Brazil Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 71. Argentina Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 72. Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 73. Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales Market Share by Countries in 2019
Figure 74. Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Countries (2015-2020)
Figure 75. Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue Market Share by Countries in 2019
Figure 76. Saudi Arabia Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 77. Egypt Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 78. Turkey Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 79. South Africa Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 80. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Sales and Growth Rate (2021-2025) (K Pcs)
Figure 81. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Revenue and Growth Rate (2021-2025) (USD Million)
Figure 82. North America Sales Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Forecast (2021-2025) (K Pcs)
Figure 83. Europe Sales Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Forecast (2021-2025) (K Pcs)
Figure 84. Asia-Pacific Sales Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Forecast (2021-2025) (K Pcs)
Figure 85. South America Sales Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Forecast (2021-2025) (K Pcs)
Figure 86. Middle East & Africa Sales Attention Deficit Hyperactivity Disorder (ADHD) Drug Market Forecast (2021-2025) (K Pcs)
Figure 87. Sales Channel: Direct Channel vs Indirect Channel